title: Effects of sildenafil citrate on five dogs with Eisenmenger's syndrome.
abstract: OBJECTIVE
  To determine the effect of sildenafil for dogs with Eisenmeger's syndrome and secondary erythrocytosis.
  
  
  METHODS
  This is a prospective, single arm, open-label study. Five clinical dogs with Eisenmeger's syndrome and secondary erythrocytosis were included. New York Heart Association functional class, packed cell volume, pulmonary artery acceleration time to ejection time ratio and serum erythropoietin concentration were evaluated before and after sildenafil therapy (0·5 mg/kg, twice a day).
  
  
  RESULTS
  New York Heart Association functional class was significantly improved after one (median 2; range 1 to 2, P=0·031) and three months (median 2; range 1 to 2, P=0·031) of sildenafil therapy, compared with the baseline (median 3, range 2 to 3). Packed cell volume was significantly decreased after three months (median 59%; range 56 to 63, P=0·031) of therapy, compared with the baseline (median 71%; range 58 to 74). Acceleration time to ejection time ratio had increased and serum erythropoietin concentration had decreased particularly after 1 month of therapy, but there was no statistical significance.
  
  
  CONCLUSIONS
  Sildenafil improved the clinical signs and secondary erythrocytosis in dogs with Eisenmeger's syndrome. Sildenafil therapy could be a useful treatment for dogs with Eisenmeger's syndrome.
authors: Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Sciences, Graduate School of Veterinary Medicine, Hokkaido University, Hokkaido 060-0818, Japan.
authors: K
authors: K
authors: Nakamura
authors: M
authors: M
authors: Yamasaki
authors: H
authors: H
authors: Ohta
authors: N
authors: N
authors: Sasaki
authors: M
authors: M
authors: Murakami
authors: W R
authors: WR
authors: Bandula Kumara
authors: M
authors: M
authors: Takiguchi
mesh_terms: D000818:Animals; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004541:Eisenmenger Complex / Q000188:drug therapy / Q000662:veterinary*; D005260:Female; D008297:Male; D010879:Piperazines / Q000627:therapeutic use*; D011446:Prospective Studies; D011687:Purines / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate